Biotech · Private company
NeuroPro Therapeutics, Inc.
Track this companyFree. Adds NeuroPro Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- NPT 2042Phase 2 · Epilepsy, GeneralizedClinicalTrials.gov · fetched Nov 12, 2026
- NPT 2042Phase 1 · Photosensitive EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- NPT 2042 (Reference formula/Formulation 1)Phase 1 · EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
- NPT 2042 (Test formula/Formulation 2)Phase 1 · EpilepsyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042PHASE1 · COMPLETED · started Sep 29, 2025ClinicalTrials.gov NCT07222878 · fetched Nov 12, 2026
- A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence SeizuresPHASE2 · COMPLETED · started Mar 11, 2025ClinicalTrials.gov NCT06769659 · fetched Nov 12, 2026
- A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042PHASE1 · COMPLETED · started Aug 21, 2024ClinicalTrials.gov NCT06525649 · fetched Nov 12, 2026
- Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult SubjectsPHASE1 · COMPLETED · started Oct 20, 2022ClinicalTrials.gov NCT05503511 · fetched Nov 12, 2026